Synthesis of both the enantiomers of aseanostatin P5 (sarcinic acid), an inhibitor of myeloperoxidase release, and four diastereomers of aggreceride A, a platelet aggregation inhibitor.
Both the enantiomers of aseanostatin P5 (sarcinic acid), an inhibitor of myeloperoxidase (MPO) release from human polymorphonuclear leukocytes (PMN), with high optical purity were synthesized by starting from (S)-2-methylbutanol and methyl (S)-3-hydroxy-2-methylpropanoate. They were converted to four diastereomers of aggreceride A, a platelet aggregation inhibitor.
Kitahara
T
T
Department of Applied Biological Chemistry, University of Tokyo, Japan.
Aono
S
S
Mori
K
K
D005227:Fatty Acids / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D005989:Glycerides / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D009682:Magnetic Resonance Spectroscopy; D013058:Mass Spectrometry; D009195:Peroxidase / Q000037:antagonists & inhibitors*; D010974:Platelet Aggregation / Q000187:drug effects*; D013055:Spectrophotometry, Infrared; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
D005227:Fatty Acids; D005989:Glycerides; C049993:aggreceride A; C069642:aseanostatin P5; D009195:Peroxidase